已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Analysis of treatment benefits and prognostic factors for posttransplant HCC recurrence in a large Euro-American-Asian cohort

医学 内科学 肝细胞癌 比例危险模型 倾向得分匹配 回顾性队列研究 危险系数 队列 生存分析 肝移植 多元分析 置信区间 肿瘤科 外科 胃肠病学 移植
作者
Zhihao Li,I. Chen,Leonardo Centonze,Christian Tibor Josef Magyar,Woo Jin Choi,Sachin Shah,Grainne M. O’Kane,Arndt Vogel,Luciano De Carlis,Jan Lerut,Quirino Lai,Neil Mehta,Chao‐Long Chen,Gonzalo Sapisochín
出处
期刊:Liver Transplantation [Lippincott Williams & Wilkins]
卷期号:31 (4): 450-463 被引量:3
标识
DOI:10.1097/lvt.0000000000000501
摘要

Posttransplant HCC recurrence significantly impacts survival, yet its management is challenging due to limited evidence. With recent advancements in HCC treatment, updated data on managing recurrent diseases are needed. In this retrospective study across 6 centers (2000-2022), we employed Cox proportional-hazards regression and log-rank tests to assess survival differences. A prognostic score model was developed to categorize patient survival. The efficacy of tyrosine kinase inhibitors was evaluated through propensity score matching. In our study, 431 of 3349 (14%) patients with HCC who underwent transplantation developed recurrence within a median interval of 18 (IQR: 9-32) months. One hundred forty-seven (34%) underwent curative-intent treatments, 207 (48%) received palliative treatments, and 77 (18%) were given best-supportive care. Patients undergoing curative-intent treatments had better survival from the time of recurrence with a median survival of 45 (95% CI: 36-63) months and 1/3/5-year survival of 90%/56%/43% compared to those receiving noncurative treatments (median: 11 [95% CI: 10-13] mo, 1/3/5-y survival of 46%/10%/7%, log-rank p < 0.001). Patients with recurrence diagnosed in the era 2018-2022 showed improved survival over the previous era (HR 0.64 [95% CI: 0.47-0.86]). Multivariable analysis identified 5 prognostic factors: ineligibility for curative-intent treatment (HR: 3.5 [95% CI: 2.7-4.6]), recurrence within 1 year (HR: 1.7 [95% CI: 1.3-2.1]), poor tumor differentiation (HR: 1.5 [95% CI: 1.1-1.9]), RETREAT score ≥3 (HR: 1.4 [95% CI: 1.1-1.8]), and alpha-fetoprotein at recurrence ≥400 ng/mL (HR: 1.4 [95% CI: 1.1-1.9]). These factors contributed to a prognostic scoring system (0-9) that stratified patients into 3 prognosis groups. Both propensity score-matched analysis and multivariable regression indicated that lenvatinib was not statistically superior to sorafenib in terms of efficacy. Curative-intent treatments should be advocated for patients with posttransplant recurrence whenever possible. Prognostic factors linked to aggressive tumor biology significantly influence survival. Advancements in HCC management have improved survival outcomes over the past 5 years.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
哈哈哈哈完成签到,获得积分10
1秒前
哭泣的鞋子完成签到,获得积分10
5秒前
邓倩完成签到,获得积分10
6秒前
7秒前
8秒前
伯赏诗霜完成签到,获得积分10
9秒前
10秒前
玛卡巴卡发布了新的文献求助10
11秒前
柔弱的铅笔完成签到,获得积分10
12秒前
平淡的灵完成签到 ,获得积分10
13秒前
sinewaves完成签到,获得积分10
15秒前
伯赏诗霜发布了新的文献求助10
15秒前
17秒前
17秒前
无极微光的应助被samantha采纳,获得20
18秒前
科研通AI65的应助被科研通管家采纳,获得10
21秒前
科研通AI2S的应助被科研通管家采纳,获得10
21秒前
21秒前
21秒前
33发布了新的文献求助10
21秒前
23秒前
岸边完成签到,获得积分10
24秒前
浮云发布了新的文献求助20
24秒前
25秒前
28秒前
学霸业的应助被Agoni采纳,获得10
28秒前
欢喜的铭完成签到,获得积分10
28秒前
好运常在完成签到 ,获得积分10
28秒前
29秒前
31秒前
领导范儿的应助被熊猫奇思采纳,获得10
32秒前
iman完成签到,获得积分10
32秒前
英姑的应助被33采纳,获得10
32秒前
kane浅发布了新的文献求助10
32秒前
小二郎的应助被如意的灵阳采纳,获得10
34秒前
iman发布了新的文献求助10
36秒前
我是老大的应助被忧郁的人英采纳,获得10
37秒前
隐形的吐司的应助被浮云采纳,获得20
39秒前
oc666888完成签到,获得积分10
40秒前
犹豫山菡完成签到,获得积分10
46秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194894
求助须知:如何正确求助?哪些是违规求助? 9580685
关于积分的说明 21872290
捐赠科研通 7794613
什么是DOI,文献DOI怎么找? 3437801
关于科研通互助平台的介绍 2561143
邀请新用户注册赠送积分活动 2484511